Early involvement of Medical Affairs in the product lifecycle is not just beneficial – it is mission critical. In the swiftly changing realm of advanced therapies like biosimilars, rare disease molecules, and cell and gene therapies, a strong scientific interpretation and orientation is essential. Medical Affairs teams are stepping up to this challenge, actively shaping the trajectory of new interventions right from their inception.
Gone are the days when Medical Affairs merely acted as a liaison between pharmaceutical companies and healthcare professionals. Today, Medical Affairs teams are indispensable strategic partners, deeply involved in crafting the very foundation of a product’s journey.
This article discusses the evolving role of Medical Affairs in shaping the healthcare landscape. She highlights how drug manufacturers should:
- Drive integrated evidence strategies,
- Build medicalized engagement strategies and
- Harness the power of medical insights to adapt to market demands.
Download the article to learn how Medical Affairs teams and activities redefine healthcare delivery and serve as a vital link between clinical deployment and product commercialization to improve patient outcomes.
Author Team
EVERSANA employs a team of over 6000 professionals across 20+ locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter…